Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FGFR2 Gene Fusion/Rearrangement Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement
Interventions
TAS-120
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
La Jolla, California • Tampa, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced May 21, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Interventions
derazantinib
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced May 21, 2026, 11:08 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Solid Tumor, Metastatic Cholangiocarcinoma
Interventions
Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Drug
Lead sponsor
Tyra Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced May 21, 2026, 11:08 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements
Interventions
Futibatinib, Cisplatin, Gemcitabine
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Duarte, California • Louisville, Kentucky • Albuquerque, New Mexico + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced May 21, 2026, 11:08 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions
Lirafugratinib
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 11:08 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation
Interventions
Pemigatinib, Durvalumab
Drug
Lead sponsor
Mehmet Akce
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Birmingham, Alabama • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 11:08 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Amplification, FGFR2 Gene Short Variants, FGFR3 Gene Fusion/Rearrangement, FGFR3 Gene Amplification, FGFR3 Gene Short Variants, FGFR2 Genetic Alterations, FGFR3 Genetic Alterations, Advanced Solid Tumors
Interventions
CGT4859
Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 11:08 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
FGFR2 Amplification, FGFR2 Gene Mutation, FGFR2 Gene Fusion/Rearrangement, FGFR2 Gene Translocation, FGFR2 Gene Activation, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma, Other Solid Tumors, Adult
Interventions
RLY-4008
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced May 21, 2026, 11:08 PM EDT